Compare Cytokinetics Inc (CYTK) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Unity Software Inc — how do they compare? Cytokinetics Inc trades at $62.64 (market cap $8.62B), while Unity Software Inc trades at $46.49 (market cap $20.20B). The key difference: Unity Software Inc is far larger — about 2.3× Cytokinetics Inc's market cap, and Unity Software Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Unity Software Inc for 50 Days on average.
| CYTK | U | |
|---|---|---|
Market Cap | $8.62B | $20.20B |
Volume | 2,594,626 | 15,432,191 |
Sector | Health | Technology |
52-Week High | $87.26 | $49.47 |
52-Week Low | $54.76 | $17.13 |
Typical Hold Time | 19 Days | 50 Days |
Enterprise Value | $8.72B | $20.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
Unity Software (U) trades at $45.44, up 1.09% on the day, with a bullish technical signal and strong analyst support. The stock is near its pivot point of $45, with immediate resistance at $46. Fundamentally, revenue reached $1.85B in 2025, but the company reported a net loss of -$402.77M, though losses are narrowing year-over-year. Recent news highlights momentum from Meta VR Glasses support and positive sector sentiment.
Outlook: Strong buy consensus (82% of analysts) and a $46.54 price target suggest upside, but persistent losses and high valuation ratios pose risks. Investment appeal hinges on revenue growth and path to profitability, while competitive and execution risks remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
